Coherent Market Insights

Global Recombinant DNA Technology Market - Demographic Data and Industry Growth Statistics Until 2025

The global recombinant DNA technology market is estimated to be valued at US$ 106.8 billion in 2017, and is expected to exhibit a robust CAGR of 7.9% during the forecast period (2017 – 2025).


Seattle, WA -- (SBWIRE) -- 10/01/2019 -- Global Recombinant DNA Technology Market, by Product Type (Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell and Gene Therapy, and Gene Editing), by Application (Therapeutics, Agriculture, and Research), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, and Forecast to 2025

Recombinant DNA technology or rDNA refers to joining DNA molecules from different sources to generate products for human by inserting them into a host organism. The rDNA technology has been crucial in terms of research and develop and has led to advances in number of fields including agriculture and drug development. It has introduced new classes of organism namely living modified organism (LMO) and genetically modified organism (GMO). These organisms can assist in developing genetically modified crops (BT cotton), bio pesticides, biofuel, cloned animals, and gene therapy. Moreover, rDNA technology enabled biopharmaceutical industry towards development numerous rDNA products such as CAR-T cell therapy and biospecific and monoclonal antibodies.

Get PDF Brochure of Research Insights @

The global recombinant DNA technology market is estimated to be valued at US$ 106.8 billion in 2017, and is expected to exhibit a robust CAGR of 7.9% during the forecast period (2017 – 2025).

Increasing technological advancements is accelerating the production of novel products, which is expected to drive growth of the market

The tremendous advancements combined with wide range of applications to treat life-threatening diseases such as cancer, diabetes and infectious diseases are expected to drive the global recombinant DNA technology market growth during the forecast period. According to the Global Diabetes Community, in 2017, around 422 million adults were suffering from diabetes across the globe. According to the same source, the number is expected to escalate to 642 million by 2040. Furthermore, according to the World Health Organization (WHO), around 1.5 million deaths were directly caused due to diabetes and another 2.2 million deaths were caused due to hyperglycemia or high blood glucose levels. Moreover, technological advancement in recombinant technologies have enabled the development of long-acting therapeutic proteins for drug development and introduced gene therapy, which is a novel molecular medicine. This is expected to drive growth of the global recombinant DNA technology market by creating a positive impact in the treatment of genetic diseases. Moreover, the novel gene editing tool, CRISPR, can be used to target eradication of abnormal genes in human cells and has provided researchers an impressive way to make precise changes to DNA of microbes, plants, mice, dogs, and human cells.

Recombinant DNA technology has also introduced high yielding, insect- and heat-resistance crop varieties such as such as soybean, maize, cotton, and rice, which require limited herbicide, thus lowering the cost of agriculture. Moreover, rDNA technology has been used to create vitamin A-enriched (golden) rice to limit the widely prevalent diseases such as Vitamin A deficiency (VAD), thus proving to be a breakthrough to fight against malnutrition. According to the Golden Rice Humanitarian Board, in 2016, VAD has affected over 140 million pre-school children in 118 countries and over 7 million pregnant women. It is rather a leading cause of child blindness in emerging economies.
However, high cost and side effects related to gene therapies such as cytokine release syndrome (CRS) or neurological toxicities are expected to hinder the market growth during the forecast period. According to the survey by CNBC LLC, in January 2018, the initial treatment cost of for the two approved CAR-T cell therapies developed by Novartis AG and Gilead Sciences is around US$ 475,000 and US$ 373,000 per patient respectively.

Read Detailed Index of Research Study @

Increasing R&D activities and growing growth strategies such as collaborations among market players is expected propel the global recombinant DNA technology market growth

Key players in the market are focused on growth strategies such as acquisitions and collaborations with leading biopharmaceutical companies and research institutes for the development of novel therapeutics based on rDNA technology. For instance, in 2017, Sanofi acquired Protein Services, in order to add a promising product 'Flublok' (Influenza Vaccine) to its vaccine portfolio. It is the only U.S. Food and Drug Administration-approved recombinant protein-based influenza vaccine. Furthermore, in 2014, Pfizer, Inc. and Massachusetts Institute of Technology (MIT) entered into a collaboration for advance drug discovery and development technologies through recombinant DNA technology to treat various disease.

Furthermore, various research organizations are launching initiatives and providing research grants for the development of novel therapeutics, which is expected to drive growth of the global recombinant DNA technology market over the forecast period. For instance, in March 2017, the University of Pennsylvania received US$ 16.3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a recombinant DNA technology-based HIV vaccine. Moreover, in 2015, Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) collaborated to focus on accelerating early detection and treatment for patients by developing personalized vaccines for a wide range of conditions such as infectious disease, cardiovascular, diabetes, neurology, and metabolic diseases. In 2015, the National Academy of Sciences and the National Academy of Medicine launched a major initiative to guide new research involving human gene-editing technologies, such as CRISPR-Cas9, which could introduce promising new treatments for disease.

Global Recombinant DNA Technology Market Key Players

Major players operating in the global recombinant DNA technology market are Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company.

Buy Now This Report @

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.